Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma

Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chic... Author: VJHemOnc Added: 07/30/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts